

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

Human CCL5/RANTES Antibody

RRID:AB_354440

Type: Antibody

Proper Citation

R and D Systems Cat# AF-278-NA, RRID:AB_354440

Antibody Information

URL: http://antibodyregistry.org/AB_354440

Proper Citation: R and D Systems Cat# AF-278-NA, RRID:AB_354440

Target Antigen: CCL5/RANTES

Host Organism: Goat

Clonality: polyclonal

Comments: Applications: Western Blot, Simple Western, Immunohistochemistry, Neutralization, Immunocytochemistry

Antibody Name: Human CCL5/RANTES Antibody

Description: This polyclonal targets CCL5/RANTES

Target Organism: Human

Antibody ID: AB_354440

Vendor: R and D Systems

Catalog Number: AF-278-NA

Alternative Catalog Numbers: AF-278-SP

Record Creation Time: 20250820T011216+0000

Record Last Update: 20250820T101813+0000

Ratings and Alerts

No rating or validation information has been found for Human CCL5/RANTES Antibody.

No alerts have been found for Human CCL5/RANTES Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Le Pelletier L, et al. (2025) C-C chemokine ligand 5 from women subcutaneous adipose tissue has a central role in vascular aging. Cardiovascular diabetology, 24(1), 295.

Xiong Z, et al. (2024) Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience, 27(5), 109674.

Jiang SS, et al. (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell host & microbe, 31(5), 781.

Jang HJ, et al. (2023) A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(11), 2052.

Topper MJ, et al. (2023) Derivation of CD8+ T??cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis. iScience, 26(7), 107095.